CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) wo ...
Phase 1, Phase 2
Madrid, Comunidad de Madrid, Spain and 23 other locations
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...
Phase 1, Phase 2
Madrid, Other, Spain and 49 other locations
with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...
Phase 3
Madrid, Spain and 75 other locations
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Madrid, Spain and 199 other locations
in patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC), refractory to ...
Phase 2
Madrid, Spain and 9 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Madrid, Spain and 228 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Madrid, Spain and 516 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Madrid, Spain and 109 other locations
after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...
Phase 2
Madrid, Spain and 121 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Madrid, Spain and 505 other locations
Clinical trials
Research sites
Resources
Legal